Serum CETP concentration is not associated with measures of body fat: The NEO study.

[1]  Jingyuan Fu,et al.  Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells , 2015, Hepatology.

[2]  Facc,et al.  Cholesterol Ester Transfer Protein Inhibition by TA-8995 , 2015 .

[3]  P. Ridker.  LDL cholesterol: controversies and future therapeutic directions , 2014, The Lancet.

[4]  Taija Finni,et al.  Body composition in 18‐ to 88‐year‐old adults—comparison of multifrequency bioimpedance and dual‐energy X‐ray absorptiometry , 2014, Obesity.

[5]  Margreet Kloppenburg,et al.  The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection , 2013, European Journal of Epidemiology.

[6]  B. Heitmann,et al.  The use of bioelectrical impedance analysis for body composition in epidemiological studies , 2013, European Journal of Clinical Nutrition.

[7]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[8]  T. V. van Berkel,et al.  Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. , 2012, Biochemical pharmacology.

[9]  G. Frühbeck,et al.  Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity , 2012, International Journal of Obesity.

[10]  H. Pijl,et al.  Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Plasma CETP and Increases Apolipoprotein AI Levels Without Improving the Cholesterol Efflux Properties of HDL , 2011, Diabetes Care.

[11]  N. Terasaka,et al.  LXRalpha regulates human CETP expression in vitro and in transgenic mice. , 2010, Atherosclerosis.

[12]  B. Wolfe,et al.  Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. , 2010, Journal of lipid research.

[13]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[14]  A. Kontush,et al.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.

[15]  B. S. Mohammed,et al.  Plasma Lipid Transfer Enzymes in Non-Diabetic Lean and Obese Men and Women , 2009, Lipids.

[16]  B. Neuschwander‐Tetri,et al.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.

[17]  J. Jukema,et al.  Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[18]  John A Wagner,et al.  Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies , 2007, The Lancet.

[19]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[20]  J. Jukema,et al.  Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Published, JLR Papers in Press, May 24, 2007. , 2007, Journal of Lipid Research.

[21]  J. Jukema,et al.  Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[22]  T. Tzotzas,et al.  Early Decreases in Plasma Lipid Transfer Proteins During Weight Reduction , 2006, Obesity.

[23]  Thomas Lumley,et al.  Analysis of Complex Survey Samples , 2004 .

[24]  A. Zwinderman,et al.  The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. , 2004, Atherosclerosis.

[25]  Elisabeth Naschberger,et al.  Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification , 2004, Clinical chemistry and laboratory medicine.

[26]  C. Packard,et al.  Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. , 2003, Atherosclerosis.

[27]  W. Saris,et al.  Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. , 2003, Journal of clinical epidemiology.

[28]  S. Going,et al.  Cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase activities in hispanic and anglo postmenopausal women: associations with total and regional body fat. , 2003, Metabolism: clinical and experimental.

[29]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[30]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[31]  A. Tall,et al.  Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. , 2000, The Journal of clinical investigation.

[32]  H. Vidal,et al.  Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. , 2000, Biochimica et biophysica acta.

[33]  M. Kawai,et al.  Body mass index (weight/height2) or percentage body fat by bioelectrical impedance analysis: which variable better reflects serum lipid profile? , 1999, International Journal of Obesity.

[34]  R. McPherson,et al.  Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. , 1998, Atherosclerosis.

[35]  C. Bouchard,et al.  Visceral fat in relation to health: is it a major culprit or simply an innocent bystander? , 1997, International Journal of Obesity.

[36]  M. McDonnell,et al.  Cholesteryl ester transfer protein (CETP) mRNA abundance in human adipose tissue: relationship to cell size and membrane cholesterol content. , 1995, Journal of lipid research.

[37]  R. Roubenoff,et al.  Predicting body fatness: the body mass index vs estimation by bioelectrical impedance. , 1995, American journal of public health.

[38]  P. Gambert,et al.  Competitive enzyme-linked immunosorbent assay of the human cholesteryl ester transfer protein (CETP). , 1994, Clinica chimica acta; international journal of clinical chemistry.

[39]  S. Yamashita,et al.  Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[40]  W. Sluiter,et al.  Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism , 1994, European journal of clinical investigation.

[41]  J. Hautvast,et al.  Relative and biomarker-based validity of a food-frequency questionnaire estimating intake of fats and cholesterol. , 1993, The American journal of clinical nutrition.

[42]  A. Tall.  Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.

[43]  E L Korn,et al.  Epidemiologic studies utilizing surveys: accounting for the sampling design. , 1991, American journal of public health.

[44]  A. Tall,et al.  Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. , 1991, The Journal of biological chemistry.

[45]  C. Fielding,et al.  Cloning and sequencing of human cholesteryl ester transfer protein cDNA , 1987, Nature.

[46]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.